THU326 Subcutaneous Insulin Aspart Every 4 Hours In the Treatment Of COVID-19 Patients With Diabetic Ketoacidosis: A Retrospective Study

Disclosure: D. Chiewchalermsri: None. C. Wanittansirichok: None. C. Sriphrapradang: None. SUBCUTANEOUS INSULIN ASPART EVERY 4 HOURS IN THE TREATMENT OF COVID-19 PATIENTS WITH DIABETIC KETOACIDOSIS: A RETROSPECTIVE STUDY Introduction: COVID-19 infection increases the risk of diabetic ketoacidosis (DK...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiewchalermsri, Dararat, Wanittansirichok, Chayanin, Sriphrapradang, Chutintorn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Diabetes And Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553442/
http://dx.doi.org/10.1210/jendso/bvad114.760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553442/
http://dx.doi.org/10.1210/jendso/bvad114.760

Ejemplares similares